Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology
- 1 September 2017
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 41 (9), 1155-1166
- https://doi.org/10.1097/pas.0000000000000818
Abstract
The 2016 World Health Organization classification recognized “high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements” (double/triple-hit lymphoma [DTHL]) and “high-grade B-cell lymphoma, not otherwise specified,” which includes non-DTHL with a “blastoid” or “intermediate” cytology. Although extensively studied, many questions remain, including which cases belong in these categories, which factors mitigate their adverse prognosis, and when to perform fluorescence in situ hybridization studies. Therefore, the clinicopathologic features of 187 large B-cell lymphomas with MYC, BCL2, and BCL6 fluorescence in situ hybridization were investigated. There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM). Patients with DTHLs, but not single-hit lymphomas, had a significantly worse prognosis compared with those with NM (P=0.0079). The ES group with at least 1 rearrangement had a worse prognosis compared with the NM/ES without rearrangement group (P<0.02). Blastoid, but not intermediate cases, were enriched in DTHLs (P<0.0001) and had a significantly worse prognosis even among DTHLs (P=0.0282). The prognosis of the diffuse large B-cell lymphoma and intermediate groups was similar. International Prognostic Index score was of prognostic importance for the entire group and for DTHLs (P=0.0074). About 93% of DTHLs were of GCB type but 24% had <40% MYC+ cells. Among the DTHLs, MYC+BCL2+ double expressor cases had a worse prognosis (P=0.0328). These results highlight the importance of morphologic, phenotypic, and clinical variations among the DTHLs and suggest that a diagnosis equivalent to DTHL should not be made based solely on ES for MYC and BCL2 and/or BCL6.Keywords
This publication has 52 references indexed in Scilit:
- Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients withMYC/BCL2double hit lymphomaOncotarget, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCLCurrent Treatment Options in Oncology, 2015
- Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomasThe Lancet Oncology, 2015
- ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?Asco Educational Book, 2015
- Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysisBritish Journal of Haematology, 2015
- A clinician's guide to double hit lymphomasBritish Journal of Haematology, 2014
- Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHCHematology-American Society Hematology Education Program, 2014
- MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approachesCancer, 2014
- ‘Double‐Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patientsBritish Journal of Haematology, 2014